Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Specification
Examiner suggests applicant to update the status of parent U.S. Application No. 17/825,918 as follows:
-Paragraph [0001], Line 2: After “2022, ” insert “now issued as U.S. Patent No. 12,083,258,”.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-11 and 15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 10, 13 and 15 of U.S. Patent No. 10,946,131. Although the claims at issue are not identical, they are not patentably distinct from each other because:
The claim comparison table discusses claims and relevant difference below.
The corresponding claims of U.S. Patent No. 10,946,131 that anticipate/obviate the instant application claims are set forth below and any necessary comparison. Anticipated claims are designated as “A” wherein claim of U.S. Patent No. 10,946,131 anticipates broad instant claim of application and contains all the limitation of instant claim. Obviousness claims are designated as “O” wherein claim of U.S. Patent No. 10,946,131 with additional claim element would have been obvious to the ordinary skills in the art for the purpose of improving plasma collection process.
Claims of
Application No. 18/779,848
Claims of
U.S. Patent No. 10,946,131
Claim Comparison
1
15/10
A
2
15/10
A
3
15/10
A
4
15/10
A
5
15/10
A
6
15/10
A
7
15/10 and 13
O
8
15/10 and 13
O
9
15/10
A
10
15/10
A
11
15/10
A
15
15/10
A
Claims 1-11, 15-20 and 23-25 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3 and 5-9 of U.S. Patent No. 11,097,042. Although the claims at issue are not identical, they are not patentably distinct from each other because:
The claim comparison table discusses claims and relevant difference below.
The corresponding claims of U.S. Patent No. 11,097,042 that anticipate/obviate the instant application claims are set forth below and any necessary comparison. Anticipated claims are designated as “A” wherein claim of U.S. Patent No. 11,097,042 anticipates broad instant claim of application and contains all the limitation of instant claim. Obviousness claims are designated as “O” wherein claim of U.S. Patent No. 11,097,042 with additional claim element would have been obvious to the ordinary skills in the art for the purpose of improving plasma collection process.
Claims of
Application No. 18/779,848
Claims of
U.S. Patent No. 11,097,042
Claim Comparison
1
6/1
A
2
6/1
A
3
6/1
A
4
6/1 and 2
O
5
6/1 and 3
O
6
6/1
A
7
6/1
A
8
6/1
A
9
6/1
A
10
6/1 and 5
O
11
6/1
A
15
6/1 and 7
O
16
6/1 and 8
O
17
6/1 and 9
O
18
6/1
Q
19
6/1 and 2
O
20
6/1
A
23
6/1
A
24
6/1
A
25
6/1 and 9
O
Claims 1-10, 15-19 and 23-25 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 11,285,251. Although the claims at issue are not identical, they are not patentably distinct from each other because:
The claim comparison table discusses claims and relevant difference below.
The corresponding claims of U.S. Patent No. 11,285,251 that anticipate/obviate the instant application claims are set forth below and any necessary comparison. Anticipated claims are designated as “A” wherein claim of U.S. Patent No. 11,285,251 anticipates broad instant claim of application and contains all the limitation of instant claim. Obviousness claims are designated as “O” wherein claim of U.S. Patent No. 11,285,251 with additional claim element would have been obvious to the ordinary skills in the art for the purpose of improving plasma collection process.
Claims of
Application No. 18/779,848
Claims of
U.S. Patent No. 11,285,251
Claim Comparison
1
6/1
A
2
6/1
A
3
6/1
A
4
6/1 and 2
O
5
6/1 and 3
O
6
6/1
A
7
6/1 and 4
O
8
6/1 and 4
O
9
6/1
A
10
6/1 and 5
O
15
6/1 and 7
O
16
6/1 and 8
O
17
6/1 and 9
O
18
6/1
Q
19
6/1 and 2
O
23
6/1
A
24
6/1
A
25
6/1 and 9
O
Claims 1-12 and 15-29 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 and 22-23 of U.S. Patent No. 11,369,724. Although the claims at issue are not identical, they are not patentably distinct from each other because:
The claim comparison table discusses claims and relevant difference below.
The corresponding claims of U.S. Patent No. 11,369,724 that anticipate/obviate the instant application claims are set forth below and any necessary comparison. Anticipated claims are designated as “A” wherein claim of U.S. Patent No. 11,369,724 anticipates broad instant claim of application and contains all the limitation of instant claim. Obviousness claims are designated as “O” wherein claim of U.S. Patent No. 11,369,724 with additional claim element would have been obvious to the ordinary skills in the art for the purpose of improving plasma collection process.
Claims of
Application No. 18/779,848
Claims of
U.S. Patent No. 11,369,724
Claim Comparison
1
9/1
A
2
9/1
A
3
9/1
A
4
9/1 and 2
O
5
9/1 and 3
O
6
9/1 and 4
O
7
9/1 and 5
O
8
9/1 and 6
O
9
9/1 and 7
O
10
9/1 and 8
O
11
9/1
A
12
9/1 and 10
O
15
9/1 and 11
O
16
91 and 12
O
17
9/1 and 13
O
18
9/1 and 14
O
19
9/1 and 15
O
20
9/1 and 16
O
21
9/1 and 17
O
22
9/1 and 18
O
23
9/1
A
24
9/1
A
25
9/1 and 22
O
26
9/1 and 23
O
27
9/1
A
28
9/1
A
29
9/1
A
Allowable Subject Matter
Claims 13-14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN KIM whose telephone number is (571)272-1142. The examiner can normally be reached Maxi Flex.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, INSUK BULLOCK can be reached on 571-272-5954. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/John Kim/Primary Examiner, Art Unit 1772
JK
9/26/26
